FDA Approval Alert: The Need-to-Know | Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

In March 2025, the FDA approved cabozantinib as a treatment for adult and pediatric patients 12 years or older with previously treated, unresectable or locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNETs) and well-differentiated extra-pancreatic NETs (epNETs).

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors
Article
Mar 26, 2025 12:50 PM
Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.